We live in an era where AI is accelerating drug discovery at an unprecedented pace. But for the patient waiting at the other end, the journey to actually receiving that therapy is often stalled by a complex web of distribution, reimbursement, and PBM hurdles.
In episode #256 of the pharmaphorum Podcast, host Nicole Raleigh sits down with D2 Solutions' CEO Dean Erhardt, to discuss the critical disconnect between drug discovery and the reality of patient access. With nearly 40 years of experience spanning payers, distributors, and PBMs, Dean provides a comprehensive look at how the life sciences industry can evolve to better serve patients, particularly those requiring complex specialty medicines.
Why patient access is currently lagging behind the rapid scientific advancements in new therapy discovery
Insights into the impact of price protection guarantees and the evolving role of PBMs in the specialty landscape
A look at patient access today vs. tomorrow and how we move toward a more integrated model for manufacturers and pharmacies
We are at a point where science has outpaced the system. We can find the cure, but can we get it to the patient's front door? That's the billion-dollar question." - Dean Erhardt
-
This podcast is available on most all platforms where you listen to your podcasts, including Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and for download on the pharmaphorum website.